# TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

> **NCT05108870** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 35 (actual)

## Conditions studied

- Human Papilloma Virus
- HPV
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **DRUG:** HB-201
- **DRUG:** HB-202
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **PROCEDURE:** Transoral Robotic Surgery

## Key facts

- **NCT ID:** NCT05108870
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-22
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05108870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05108870, "TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05108870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*